Author

Laurent J. S. De Backer

Sanford Burnham Prebys Medical Discovery InstituteORCID 0000-0002-2243-2408Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

Allison S. LimpertiD· 2 shared Douglas J. SheffleriD· 2 shared Fabiana Izidro LayngiD· 2 shared Lester J. LambertiD· 2 shared Maria Celeridad· 2 shared Nicholas D. P. CosfordiD· 2 shared A. ChaikuadiD· 1 shared Alexander Aleshin· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

Allison S. LimpertORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cell BiologybioRxivPreprintOct 7, 2026

Reversible, Orally Bioavailable Small-Molecule Inhibitors Occupy the Substrate Tunnel of the Thioesterase Domain of Fatty Acid Synthase

Joseph Fromm, Alexander Aleshin, Lester J. Lambert…·Nicholas D. P. Cosford

This paper reports the discovery of SBP-5917, a reversible FASN-TE inhibitor with submicromolar potency and cellular target engagement.

DOI 10.64898/2026.10.01.756096

experimental assaydrug response / drug discovery

Cancer BiologyACS Chemical BiologyPeer-reviewedFeb 12, 2026

Synthesis and Characterization of ULK1/2 Kinase Inhibitors that Inhibit Autophagy and Upregulate Expression of Major Histocompatibility Complex I for the Treatment of Non-Small Cell Lung Cancer

Fabiana Izidro Layng, Huiyu Ren, Nicole A. Bakas…·Nicholas D. P. Cosford

The paper reports the design, synthesis, and characterization of new ULK1/2 inhibitors that inhibit autophagy and upregulate MHC I in NSCLC cells, supporting their potential as cancer therapeutics.

3 citationstop 3%

humanexperimental assay